Synergistic Effect of Berberine-Based Chinese Medicine Assembled Nanostructures on Diarrhea-Predominant Irritable Bowel Syndrome In Vivo

Diarrhea-predominant irritable bowel syndrome (IBS-D) is one common chronic functional disease of the digestive system with limited treatments. The microbiota-gut-brain axis (MGBA) has a central function in the pathogeny of IBS-D, which includes the participation of many various factors, such as bra...

Full description

Saved in:
Bibliographic Details
Main Authors: Lei Li (Author), Herong Cui (Author), Tong Li (Author), Jinchai Qi (Author), Hongshan Chen (Author), Feng Gao (Author), Xuehao Tian (Author), Yunnong Mu (Author), Rui He (Author), Siyuan Lv (Author), Fuhao Chu (Author), Bing Xu (Author), Penglong Wang (Author), Haimin Lei (Author), Hongri Xu (Author), Chengxiang Wang (Author)
Format: Book
Published: Frontiers Media S.A., 2020-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d9f0eb1aaf634a6e9b21ea1d12d742c7
042 |a dc 
100 1 0 |a Lei Li  |e author 
700 1 0 |a Lei Li  |e author 
700 1 0 |a Herong Cui  |e author 
700 1 0 |a Tong Li  |e author 
700 1 0 |a Jinchai Qi  |e author 
700 1 0 |a Hongshan Chen  |e author 
700 1 0 |a Feng Gao  |e author 
700 1 0 |a Xuehao Tian  |e author 
700 1 0 |a Yunnong Mu  |e author 
700 1 0 |a Rui He  |e author 
700 1 0 |a Siyuan Lv  |e author 
700 1 0 |a Fuhao Chu  |e author 
700 1 0 |a Bing Xu  |e author 
700 1 0 |a Penglong Wang  |e author 
700 1 0 |a Haimin Lei  |e author 
700 1 0 |a Hongri Xu  |e author 
700 1 0 |a Chengxiang Wang  |e author 
245 0 0 |a Synergistic Effect of Berberine-Based Chinese Medicine Assembled Nanostructures on Diarrhea-Predominant Irritable Bowel Syndrome In Vivo 
260 |b Frontiers Media S.A.,   |c 2020-08-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2020.01210 
520 |a Diarrhea-predominant irritable bowel syndrome (IBS-D) is one common chronic functional disease of the digestive system with limited treatments. The microbiota-gut-brain axis (MGBA) has a central function in the pathogeny of IBS-D, which includes the participation of many various factors, such as brain-gut peptides (BGPs), immune inflammation, and intestinal flora. Inspired by the drug combination in traditional Chinese medicine (TCM), our previous study discovered that berberine (BBR) and baicalin (BA) could form natural self-assemblies as BA-BBR nanoparticles (BA-BBR NPs) and showed synergistic effects against IBS-D. Here, we investigated the synergistic effects of BA-BBR NPs on IBS-D model mice induced by chronic restraint stress plus Senna alexandrina Mill decoction with the influence on MGBA. BA-BBR NPs showed the best therapeutic effect on improving visceral hypersensitivity and diarrhea on IBS-D model mice, compared with BBR, BA, and BA/BBR mixture. Furthermore, BA-BBR NPs significantly (P<0.05) reduced the levels of 5-hydroxytryptamine (5-HT), vasoactive intestinal polypeptide (VIP) and choline acety transferase (CHAT) in colon tissues or of serum from BGPs; it lowered the expressions of the nuclear factor kappa-B (NF-κB) in colon tissues and changed the levels of basophil granulocyte (BASO) and leukomonocyte (LYMPH) in whole blood from immune inflammation; it altered the intestinal flora of Bacteroidia, Deferribacteres, Verrucomicrobia, Candidatus_Saccharibacteria, and Cyanobacteria from intestinal flora. In conclusion, BA-BBR NPs, after forming the natural self-assembly between BBR and BA, promoted the synergistic effect on IBS-D mice than the sum of BBR and BA effects, based to the formation of self-assemblies rather than the simple mixing. It further proved that synergistic effect of BA-BBR NPs on IBS-D mice might be related to BGPs, immune inflammation, and intestinal flora from three important interrelated components of MGBA. This study will provide a novel idea for the interpretation of TCM compatibility theory and provide the basis for BA-BBR NPs as a medicinal plant-derived natural and efficient nanomaterial for clinical use. 
546 |a EN 
690 |a berberine 
690 |a self-assembly 
690 |a nanostructures 
690 |a diarrhea-predominant irritable bowel syndrome 
690 |a microbiota-gut-brain axis 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 11 (2020) 
787 0 |n https://www.frontiersin.org/article/10.3389/fphar.2020.01210/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/d9f0eb1aaf634a6e9b21ea1d12d742c7  |z Connect to this object online.